Parenteral Nutrition Associated Cholestasis Is Earlier, More Prolonged and Severe in Small for Gestational Age Compared with Appropriate for Gestational Age Very Low Birth Weight Infants by 源��궓�슚 et al.
Yonsei Med J   http://www.eymj.org   Volume 54   Number 4   July 2013 839
Original Article http://dx.doi.org/10.3349/ymj.2013.54.4.839pISSN: 0513-5796, eISSN: 1976-2437          Yonsei Med J 54(4):839-844, 2013
Parenteral Nutrition Associated Cholestasis Is Earlier, More 
Prolonged and Severe in Small for Gestational Age Compared with 
Appropriate for Gestational Age Very Low Birth Weight Infants
Soon Min Lee,1 Ran Namgung,1 Min Soo Park,1 Ho Sun Eun,1 Nam Hyo Kim,2 Kook In Park,1 and Chul Lee1
1Division of Neonatology, Department of Pediatrics, Severance Children’s Hospital, Yonsei University College of Medicine, Seoul;
2Department of Pediatrics, Sung-Ae General Hospital, Seoul, Korea.
Received: May 14, 2012
Revised: August 6, 2012
Accepted: September 4, 2012
Corresponding author: Dr. Ran Namgung,
Division of Neonatology, Department of 
Pediatrics, Severance Children’s Hospital, 
Yonsei University College of Medicine, 
50 Yonsei-ro, Seodaemun-gu, 
Seoul 120-752, Korea.
Tel: 82-2-2228-2050, Fax: 82-2-313-4614
E-mail: Ranng@yuhs.ac
∙ The authors have no financial conflicts of 
interest.
© Copyright:
Yonsei University College of Medicine 2013
This is an Open Access article distributed under the 
terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/ 
licenses/by-nc/3.0) which permits unrestricted non-
commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Purpose: We hypothesized that parenteral nutrition associated cholestasis (PNAC) 
would be more severe in small for gestational age (SGA) compared with appropri-
ate for gestational age (AGA) very low birth weight (VLBW) infants. Materials 
and Methods: Sixty-one VLBW infants were diagnosed as PNAC with exposure 
to parenteral nutrition with elevation of direct bilirubin ≥2 mg/dL for ≥14 days. 
Twenty-one SGA infants and 40 AGA infants matched for gestation were com-
pared. Results: Compared with AGA infants, PNAC in SGA infants was diag-
nosed earlier (25±7 days vs. 35±14 days, p=0.002) and persisted longer (62±36 
days vs. 46±27 days, p=0.048). Severe PNAC, defined as persistent elevation of 
direct bilirubin ≥4 mg/dL for more than 1 month with elevation of liver enzymes, 
was more frequent in SGA than in AGA infants (61% vs. 35%, p=0.018). The se-
rum total bilirubin and direct bilirubin levels during the 13 weeks of life were sig-
nificantly different in SGA compared with AGA infants. SGA infants had more 
frequent (76% vs. 50%, p=0.046), and persistent elevation of alanine aminotrans-
ferase. Conclusion: The clinical course of PNAC is more persistent and severe in 
SGA infants. Careful monitoring and treatment are  required for SGA infants.
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INTRODUCTION
Parenteral nutrition (PN) is essential in small premature infants during the critical 
early neonatal period to promote the growth and development. However, pro-
longed PN is associated with hepatobiliary dysfunction, particularly cholestasis. In 
very low birth weight (VLBW) infants, the rates of parenteral nutrition associated 
cholestasis (PNAC) have been reported to be as high as 50%.1
Although the mechanism is unclear, several risk factors for cholestasis have 
been identified, namely, immaturity of the biliary excretory system, absence of 
oral feeding, bacterial overgrowth or sepsis and cumulative high intake of amino 
acids and lipids.2-4
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vital signs), necrotizing enterocolitis (NEC by the modified 
Bell’s staging criteria), intraventricular hemorrhage (IVH 
included higher than grade 2 confirmed by brain ultraso-
nography or brain magnetic resonance imaging), periven-
tricular leucomalacia (PVL confirmed by brain magnetic 
resonance imaging), retinopathy of prematurity (ROP clas-
sified according to the International Classification of Acute 
Retinopathy of Prematurity) were collected. 
PN was started within the first 48 hours of life with 6% 
amino acid solution (6% Aminosteril Ped®, Boryung Phar-
ma Corp, Seoul, Korea, or Trophamine®, Choongwae Phar-
ma Corp, Seoul, Korea) and  20% lipid solution (Lipision®, 
Choongwae Pharma Corp, Seoul, Korea). The starting dose 
of amino acid or lipid was 0.5 g/kg/day, and doses were in-
creased by 0.5 g/kg/day until reaching 3.0 g/kg/day. Dex-
trose was initiated on the first day, with glucose infusion 
rate of 6-8 mg/kg/min and advanced to a maximum of 12-
14 mg/kg/min when needed. The volumes and durations of 
enteral feedings were dependent on the individual infants’ 
ability to tolerate feedings. Liver function tests, total biliru-
bin and direct bilirubin were checked at weekly intervals to 
monitor for PN complications. With the diagnosis of PNAC, 
maximal daily infusion of amino acid was lowered to less 
than 2 g/kg/day. When hypertriglycemia developed (TG 
>150 mg/dL), the maximal daily infusion of lipid was re-
duced to less than 2 g/kg/day. All medication metabolized 
by liver were analyzed.
Statistical analysis was done with the Student t-test and 
chi-square analysis for means and frequencies. Numeric 
data are presented as mean and standard deviation because 
the data were normally distributed. Serum levels of biliru-
bin at each week were analyzed using repeated measures 
ANOVA. Calculations were performed with SPSS software 
version 17.0 (SPSS Inc., Chicago, IL, USA). p-values less 
than 0.05 were considered statistically significant.
 
RESULTS
 
Severe PNAC developed in 61% of SGA infants, signifi-
cantly higher than 35% of AGA infants (OR=3.0, 95% CI, 
1.03-9.02, p=0.018) (Table 1). Maternal pregnancy induced 
hypertension was more frequent in SGA than in AGA in-
fants (67% vs. 25%, p=0.011). Common neonatal illnesses 
such as hyaline membrane disease (HMD), BPD, patent 
ductus arteriosus, sepsis, NEC, ROP, IVH and PVL were 
not significantly different between the groups (Table 2). 
The infants who are small for gestational age (SGA) or 
growth restricted are known to have a number of metabolic 
abnormalities related to the liver as compared with those 
who are appropriate for gestational age (AGA).5,6 SGA in-
fants exposed to PN have been reported to have more severe 
liver damage than AGA infants.7 Robinson and Ehrenkranz8 
reported that SGA is an independent risk factor for PNAC, 
and suggested that SGA infants require less PN for cholesta-
sis to develop. However, they did not focus on whether the 
clinical course and hepatic dysfunction would be different 
in SGA compared with AGA infants. In a recent report by 
Costa, et al.,9 SGA infants were not at higher risk of PNAC, 
and enteral intake during the first three weeks of life and 
oxygen therapy were the best predictors of PNAC.
In this study, we aim to identify whether SGA infants 
with PNAC would be different in clinical severity with he-
patic dysfunction compared with AGA VLBW infants, 
asuming the altered hepatic metabolism in growth restricted 
condition.
MATERIALS AND METHODS
　　　
Among VLBW infants admitted to the Severance Chil-
dren’s Hospital NICU from 2000 to 2007 and exposed to 
PN for more than 14 days, there were 21 SGA infants who 
fulfilled our preselection criteria of PN exposure. SGA was 
defined as a birth weight below the 10th percentile for ges-
tational age on a fetal growth chart.10 Forty AGA infants who 
had the same gestation age as the SGA infants were select-
ed for comparison as defined in blocks of one week. Exclu-
sion criteria were cholestasis attributable to congenital infec-
tion, anatomic obstruction of the hepatobiliary tract, inherited 
metabolic disorders and congenital gastrointestinal disor-
ders. Cholestasis was defined as the peak serum direct bili-
rubin greater than 2.0 mg/dL during the entire course of 
PN. All infants with cholestasis underwent liver ultrasound 
and testing for infectious hepatitis. In addition, severe PNAC 
was defined as the elevation of direct bilirubin greater than 
4.0 mg/dL for 1 month and as elevation of aspartate amino-
transferase (AST) and alanine aminotransterase (ALT) 
greater than 60 IU/L and 35 IU/L, respectively. 
As for co-morbidities, bronchopulmonary dysplasia (BPD 
by NIH classification), late onset sepsis (diagnosed after 72 
hours of life, culture proven in association with signs of 
systemic inflammatory response syndrome such as fever, 
low peripheral skin temperature, hypotension and unstable 
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When the SGA infants were compared with the AGA in-
fants, the mean age at diagnosis of cholestasis detected was 
significantly earlier (p=0.002), and the mean duration of cho-
lestasis was significantly longer in SGA infants (p=0.048). In 
SGA infants, postconceptional age of cholestasis detected 
was 32.4±2.1 wks compared to 32.4±2.1 wks of AGA in-
fants with no significant difference. The mean level of peak 
There were no differences between groups for the days 
from birth to starting PN, days from birth to starting enteral 
feedings, and age at which enteral nutrition reached 60 or 
120 kcal/kg/day. The duration of PN exposure, cumulative 
dose of parenteral amino acids and lipids, and average 
amounts of amino acid and lipid were not significantly dif-
ferent between the two groups (Table 3).
Table 1. Characteristics of VLBW Infants with PNAC between SGA and AGA Infants
 SGA (n=21) AGA (n=40) p value
Gestational age (wks) 29.2±1.9 28.2±2.0 NS
Gender (male/female) 12/9 23/17 NS
Birth weight (g)   813.6±160.7 1087.2±230.4 <0.01
Apgar score-1 min  2.3±1.6   2.7±1.6 NS
Apgar score-5 min  4.7±1.8   3.7±2.2 NS
NSVD/C-sec 2/19 15/25 NS
Duration of hospitalization (d) 118.0±61.9 114.9±43.7 NS
Maternal PIH, n (%) 14 (67) 10 (25)     0.011
Pathologic chorioamnionitis, n (%) 10 (47) 14 (35) NS
Placenta previa, n (%)   4 (18)   5 (12) NS
Deaths, n (%)   2 (10)   7 (18) NS
Severe PNAC, n (%) 13 (61) 14 (35)     0.018
VLBW, very low birth weight; PNAC, parenteral nutrition associated cholestasis; SGA, small for gestational age; AGA, appropriate for gestational age; 
NSVD, normal spontaneous vaginal delivery; C-sec, cesarean section; PIH, pregnancy induced hypertension; NS, not significant.
Table 2. Co-Morbid Factors of VLBW Infants with PNAC between SGA and AGA Infants
 SGA (n=21) AGA (n=40) p value
HMD (%) 18 (86) 38 (95)  NS
BPD (%) 17 (81) 30 (75)  NS
PDA (%)   9 (43) 19 (48)  NS
Sepsis (%)   6 (29)   4 (10)  NS
NEC (%) 16 (76) 31 (78)  NS
ROP (%) 12 (57) 16 (40)  NS
IVH (%)   7 (33) 12 (30)  NS
PVL (%)   3 (11)   6 (15)  NS
VLBW, very low birth weight; PNAC, parenteral nutrition associated cholestasis; SGA, small for gestational age; AGA, appropriate for gestational age; 
HMD, hyaline membrane disease; BPD, bronchopulmonary dysplasia; PDA, patent ductus arteriosus; NEC, necrotizing enterocolitis; ROP, retinopathy of 
prematurity; IVH, intraventricular hemorrhage; PVL, periventricular leukomalacia; NS, not significant.
Results are number of subject (%).
Table 3. Nutrition Associated Factors of VLBW Infants with PNAC between SGA and AGA Infants  
 SGA (n=21) AGA (n=40) p value
Day of EN started (d) 9.6±5.3 8.6±4.9  NS
Day of PN started (hr) 45.6±10.8 47.1±16.5  NS
Duration of PN (d) 40.8±12.4 35.4±15.8  NS
Age reaching oral 60 kcal/kg (d) 33.6±11.6 31.6±15.8  NS
Age reaching oral 120 kcal/kg (d) 58.9±13.5 61.8±14.3  NS
Average A.A amount (g/kg/d) 2.1±0.4 2.1±0.4  NS
Total A.A amount (g/kg) 59.6±22.5 63.0±16.5  NS
Average lipid amount (g/kg/d) 2.3±0.2 2.0±0.3  NS
Total lipid amount (g/kg) 83.5±25.4 78.4±21.3  NS
VLBW, very low birth weight; PNAC, parenteral nutrition associated cholestasis; SGA, small for gestational age; AGA, appropriate for gestational age; EN, 
enteral nutrition; PN, parenteral nutrition; A.A, amino acid; NS, not significant.
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DISCUSSION
In the present study, we found that SGA infants have a dif-
ferent clinical course of PNAC compared with AGA in-
fants, especially in the severity of PNAC and hepatic dys-
function. In SGA infants, PNAC is diagnosed earlier and 
persisted longer, and severe PNAC occurred more fre-
quently compared with AGA infants. The serum total bili-
rubin and direct bilirubin levels during the 13 weeks of life 
were significantly different between SGA and AGA infants. 
This difference in clinical pattern would be important in 
caring for infants with PNAC.  
In 1970’s, PNAC was reported in 50% of the infants 
weighing less than 1000 g. After 2 to 4 weeks of PN expo-
sure, PNAC occurred in 15% of the infants weighing be-
tween 1000 g and 2000 g.1 The rate is increased to 67% after 
direct bilirubin tends to be high in SGA compared with AGA 
infants, but the group difference was not significant. In 
SGA infants, the days when serum direct bilirubin levels 
reached the maximum and were normalized were not sig-
nificantly different. SGA infants had more frequent AST el-
evation (OR 4.0, 95% CI 1.02-15.81, p=0.048) and ALT el-
evation (OR 3.2, 95% CI 1.01-10.45, p=0.039), and longer 
duration of ALT elevation than AGA infants (p=0.046) (Ta-
ble 4). 
In the VLBW infants with severe PNAC, the serum total 
bilirubin and serum direct bilirubin levels were plotted over 
13 weeks of the study period. Using the repeated measured 
ANOVA, the serum total bilirubin was shown to be signifi-
cantly different between the SGA and AGA infants over the 
13 weeks of life (p<0.01). Also, serum direct bilirubin was 
significantly different between SGA and AGA infants over 
the 13 weeks of life (p<0.01) (Fig. 1). 
Table 4. Bilirubin and Liver Enzyme Associated Factors of VLBW Infants with PNAC between SGA and AGA Infants  
 SGA (n=21) AGA (n=40) p value
Age of cholestasis detected (d) 25±7 35±14 0.002
Duration of cholestasis (d)   62±36 46±27 0.048
Mean level of peak direct bilirubin (mg/dL)   6.4±5.2 4.9±3.0 0.225
Days of peak direct bilirubin reached (d)   38±33 45±18 0.118
Age of direct bilirubin normalized (d)   87±34 81±30 0.506
AST elevation, n (%) 16 (76.2) 20 (50)   0.048*
ALT elevation, n (%) 18 (85.2) 24 (60)  0.039†
Duration of AST elevation (d)   93±75 83±44 0.601
Duration of ALT elevation (d)   116±107 65±35 0.046
Peak ALT levels (IU/L)   402±700 204±339 0.349
Peak AST levels (IU/L)     575±1360   448±1063 0.736
AST, aspartate transaminase; ALT, alanine aminotransterase; VLBW, very low birth weight; PNAC, parenteral nutrition associated cholestasis; SGA, small 
for gestational age; AGA, appropriate for gestational age.
*Odds ratio (95% CI): 4.0 (1.02-15.81). 
†Odds ratio (95% CI): 3.2 (1.01-10.45).
A B
Fig. 1. Comparison of serum total bilirubin (A) and direct bilirubin (B) levels from SGA and AGA infants with PNAC. There was a significant difference in the 
serum levels of total bilirubin (p<0.01) and direct bilirubin (p<0.01) levels of SGA infants compared with AGA infants by repeated measured ANOVA. SGA, 
small for gestational age; AGA, appropriate for gestational age; PNAC, parenteral nutrition associated cholestasis; ANOVA, analysis of variance.
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growth restriction has altered hepatic fatty acid metabolism 
ratios.22,23 Increased level of glucose uptake may also alter 
glucose transporter expression and glucose homeostasis in 
liver.24 In addition, altered metabolism of copper and insuf-
ficient antioxidant activity in the liver were suggested as 
contributing factors in the development of cholestasis in 
SGA infants.25,26 A strong association between maternal hy-
pertensive disorders and reduced fetal growth, possibly due 
to vasculopathy with resulting uteroplacental insufficiency, 
has been identified.27 However, there is no significant dif-
ference in the clinical course of PNAC between the babies 
with and without pregnancy induced hypertension mother. 
In the typical course of liver toxicity in premature infants 
receiving PN, serum direct bilirubin levels reaches the peak 
levels at about 40 days of life, and serum ALT reaches the 
peak levels at about 40-60 days of life, and the level of di-
rect bilirubin falls after increasing enteral feeding.4 In our 
study, clinical course of hepatic dysfunction showed that di-
rect bilirubin reached the peak levels at about 40 days in 
both groups and normalized at about 80 days. Increase of 
direct bilirubin in SGA infants tended to be detected earlier, 
and prolonged longer, but without significance. AST/ALT 
elevation was noted for about 85 days and SGA infants had 
longer duration of elevation than AGA infants.  
Although a resolution of the jaundice and a normalization 
of liver enzymes may occur after the withdrawal of PN and 
the initiation of enteral feeding, some infants may have per-
sistent liver disease or hepatic failure. To date, several phar-
macological agents have been marketted, but no conclusive 
benefits have been documented. Ursodeoxycholic acid 
(UDCA) can decrease the duration and extent of jaundice 
and shorten the clinical course of PNAC in VLBW nonsur-
gical patients while other biochemical parameters of liver 
function are not changed.28 We also treat all patients with 
UDCA. Recently, the potential benefits of providing fish oils 
for both treatment and prevention of PNAC are supported 
by experimental data.29 In the present study, fish oil-based 
lipid formulation was not adopted yet, further consideration 
will be needed. 
Limitations of this study may be a small sample size, ret-
rospective design, and multifactorial factors of prematurity 
in relation to PNAC. 
In conclusion, SGA infants had earlier onset and longer 
duration of PNAC with hepatic dysfunction compared with 
AGA infants. Since clinical course of PNAC is more per-
sistent and severe in SGA infants, careful monitoring and 
treatment are required to reduce clinical severity of PNAC 
3 months of PN exposure. An overall associated mortality 
ranged from 3% to 14% due to hepatic failure and sepsis.11
Multifactorial risk factors for the development of PNAC 
include prematurity, lack of enteral feeding, prolonged du-
ration of PN and bacterial overgrowth.12-14 The relation be-
tween the risk of PNAC and gestational age may be due to 
physiological immaturity of neonatal liver, and impaired 
hepatic transportation and metabolism of bile acids in pre-
maturity.4 The decreased enterohepatic circulation, intesti-
nal hormone and enzyme secretion by enteral starvation 
lead to further decreases in bile flow, causing cholestasis.4 
Sepsis-related damage to hepatocytes is triggered by lipo-
polysaccharides of endotoxins, and cytokines induces hepa-
totoxicity and 30% increase in the bilirubin level.14,15 In ad-
dition, liver toxicity may result from PN components such 
as amino acid, lipid, and other materials.2,16 Phytosterols 
contained in lipid emulsions may also have a deleterious ef-
fect on biliary secretions, and intravenous infusions of ami-
no acids result in decreased bile output because hepatocytes 
preferentially take up sodium-dependent amino acids to 
bile salts.17 Increased dextrose concentrations in the PN 
cause alterations in hepatic morphology and plasma levels 
of insulin and glucagon in adult rats.18 We did not find the 
difference in PN components between SGA and AGA in-
fants in regard with liver injury. Both of them showed no 
difference in the use of medications which are metabolized 
by liver. VLBW Infants with SGA have higher mortality 
rates than AGA infants and are at significant risk for re-
duced postnatal growth and development as well as acute 
and chronic morbidities such as HMD, BPD and ROP.5,19-21 
Some studies showed SGA as a risk factor for PNAC,7 
whereas others not a risk factor for PNAC.8 In our study, 
severe PNAC developed three times greater in SGA infants 
than AGA infants. Furthermore, we noted the difference of 
clinical course with hepatobilliary dysfunction in SGA in-
fants, and found that SGA infants had a higher risk for se-
vere PNAC.  
Because the mechanisms for the development of PNAC 
are not fully understood, investigations into the pathways in 
SGA infants may reveal important information about the 
pathophysiology and potential effective therapies of PNAC. 
Impaired perfusion of the liver in utero may affect the hepa-
tocyte function and tolerance to feedings in the very preterm 
infant.7 SGA infants may have decreased capacity to utilize 
or metabolize protein and may be more sensitive to exces-
sive protein load compared to AGA infants, possibly leading 
to hepatocellular dysfunction.6 Fetal rat with intrauterine 
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ciated cholestasis. Nat Clin Pract Gastroenterol Hepatol 2007;4: 
277-87.
15. Beath SV, Davies P, Papadopoulou A, Khan AR, Buick RG, Cork-
ery JJ, et al. Parenteral nutrition-related cholestasis in postsurgical 
neonates: multivariate analysis of risk factors. J Pediatr Surg 
1996;31:604-6.
16. Willis TC, Carter BA, Rogers SP, Hawthorne KM, Hicks PD, 
Abrams SA. High rates of mortality and morbidity occur in infants 
with parenteral nutrition-associated cholestasis. JPEN J Parenter 
Enteral Nutr 2010;34:32-7. 
17. Bucuvalas JC, Goodrich AL, Blitzer BL, Suchy FJ. Amino acids 
are potent inhibitors of bile acid uptake by liver plasma membrane 
vesicles isolated from suckling rats. Pediatr Res 1985;19:1298-
304.
18. Li S, Nussbaum MS, Teague D, Gapen CL, Dayal R, Fischer JE. 
Increasing dextrose concentrations in total parenteral nutrition 
(TPN) causes alterations in hepatic morphology and plasma levels 
of insulin and glucagon in rats. J Surg Res 1988;44:639-48.
19. Aucott SW, Donohue PK, Northington FJ. Increased morbidity in 
severe early intrauterine growth restriction. J Perinatol 2004;24: 
435-40.
20. Bernstein IM, Horbar JD, Badger GJ, Ohlsson A, Golan A. Mor-
bidity and mortality among very-low-birth-weight neonates with 
intrauterine growth restriction. The Vermont Oxford Network. Am 
J Obstet Gynecol 2000;182(1 Pt 1):198-206.
21. Regev RH, Lusky A, Dolfin T, Litmanovitz I, Arnon S, Reichman 
B; Israel Neonatal Network. Excess mortality and morbidity 
among small-for-gestational-age premature infants: a population-
based study. J Pediatr 2003;143:186-91.
22. Lane RH, Flozak AS, Ogata ES, Bell GI, Simmons RA. Altered 
hepatic gene expression of enzymes involved in energy metabo-
lism in the growth-retarded fetal rat. Pediatr Res 1996;39:390-4.
23. Lane RH, Tsirka AE, Gruetzmacher EM. Uteroplacental insuffi-
ciency alters cerebral mitochondrial gene expression and DNA in 
fetal and juvenile rats. Pediatr Res 2000;47:792-7.
24. Lane RH, Crawford SE, Flozak AS, Simmons RA. Localization 
and quantification of glucose transporters in liver of growth-re-
tarded fetal and neonatal rats. Am J Physiol 1999;276(1 Pt 1): 
E135-42.
25. Cordano A. Clinical manifestations of nutritional copper deficien-
cy in infants and children. Am J Clin Nutr 1998;67(5 Suppl): 
1012S-6S.
26. Peña MM, Lee J, Thiele DJ. A delicate balance: homeostatic con-
trol of copper uptake and distribution. J Nutr 1999;129:1251-60.
27. Piper JM, Langer O, Xenakis EM, McFarland M, Elliott BD, 
Berkus MD. Perinatal outcome in growth-restricted fetuses: do 
hypertensive and normotensive pregnancies differ? Obstet Gyne-
col 1996;88:194-9.
28. Chen CY, Tsao PN, Chen HL, Chou HC, Hsieh WS, Chang MH. 
Ursodeoxycholic acid (UDCA) therapy in very-low-birth-weight 
infants with parenteral nutrition-associated cholestasis. J Pediatr 
2004;145:317-21.
29. Koletzko B, Goulet O. Fish oil containing intravenous lipid emul-
sions in parenteral nutrition-associated cholestatic liver disease. 
Curr Opin Clin Nutr Metab Care 2010;13:321-6.
and possibly to prevent hepatic failure.
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